Indiana Medicaid: HIP, Hoosier Healthwise, Hoosier Care Connect and PathWays
Indiana Medicaid covered 1,417,317 Hoosiers in October 2026 (FSSA enrollment report). Its rule excludes "Anorectics or any agent used to promote weight loss" (405 IAC 5-24-3, quoted in the IHCP pharmacy module), and one drug list applies to every Medicaid plan (drug list, November 1, 2026). Under the criteria in force since July 1, 2026, Zepbound® is covered with prior authorization for moderate to severe obstructive sleep apnea in adults with a BMI of 30 or more and no diabetes, and Wegovy® after a heart attack, stroke or artery disease, or for MASH liver disease; both are labeled "NOT COVERED EXCLUSIVELY FOR WEIGHT LOSS" (Optum Rx criteria). New GLP-1 criteria apply to requests from January 1, 2027 (bulletin BT2026184); their text wasn't published when we checked. Members under 21 can be considered case by case (LSA fiscal note, HB 1202).
On July 30, 2026 Governor Mike Braun directed FSSA to join CMS's BALANCE model: drugmakers supply select GLP-1s "for $245 per member per month," and "Indiana will pay just $85.16 per person per month." "Additional implementation details, including eligibility criteria and timing, will be announced as the agreement is finalized" (Governor's release). CMS lists the KwikPen® form of Zepbound®, not the vials, and says the model "will not guarantee coverage for any individual" (CMS, BALANCE). Until Indiana publishes its criteria, Medicaid covers no GLP-1 for weight loss alone.
The State employee plan
"Effective January 1, 2026, GLP-1 drugs used for weight loss will no longer be covered under the State's pharmacy benefit," the State Personnel Department says (INSPD, prescription coverage). The 2026 CVS Caremark certificate lists "Anti-Obesity GLP1 Drugs" among its exclusions (CVS Caremark plan certificate 2026), the 2027 open-enrollment page repeats the rule (INSPD, 2027 open enrollment), and cash purchases "cannot be applied toward your deductible and out of pocket maximum."
Universities and job plans
Indiana University's plans pay their own claims; CVS Caremark removed Zepbound® from IU's formulary effective July 1, 2025 and moved existing approvals to Wegovy® (IU Today, June 5, 2025), so ask IU Human Resources what applies now. Purdue covers weight-loss drugs only through its Center for Healthy Living program, where Zepbound® costs $159 a month in 2026 (Purdue HR).
No Indiana law requires any plan to cover obesity drugs. Three 2025 bills died in committee: HB 1202 (Medicaid coverage), HB 1138 (State employee plan coverage) and SB 132 (a childhood obesity study) (HB 1202; HB 1138; SB 132). Self-funded job plans follow federal law, not Indiana's (our reading). CVS Caremark added Zepbound® back to its commercial lists on October 1, 2026 "for plan sponsors who elect to provide coverage" (CVS Health, May 28, 2026). If your plan does cover a GLP-1, a 2025 Indiana law makes insured plans answer drug prior-authorization requests within 48 hours, 24 if urgent, and keep an approval for at least a year (SEA 480-2025, Indiana Code, Title 27).
Plans you buy yourself
Indiana's benchmark plan for 2025 to 2027 excludes "Any Drug which is primarily for weight loss" (CMS, benchmark plans). For 2027, four carriers sell marketplace plans (Anthem, Coordinated Care, UnitedHealthcare and, new, AmeriHealth Caritas); Cigna and CareSource leave, and approved rates rise 17.5% on average (Indiana Department of Insurance). Open enrollment runs November 1, 2026 to January 15, 2027; enroll by December 15 for coverage from January 1 (HealthCare.gov).
Medicare and the GLP-1 Bridge
1,428,729 Hoosiers had Medicare in July 2026 (CMS enrollment data). Part D members 18 or older who meet its BMI criteria pay $50 a fill for Foundayo™, Wegovy® or the Zepbound® KwikPen® until December 31, 2027; it excludes type 2 diabetes, moderate to severe sleep apnea and fatty liver disease, and single-dose Zepbound® vials or pens (Medicare.gov; CMS). Compounded drugs aren't on its list. Free help: Indiana SHIP, (800) 452-4800 (Indiana SHIP).
TRICARE, the VA and tribal care
TRICARE "covers Wegovy, Saxenda, and Zepbound for weight management" with a network prescriber and prior authorization, but not for TRICARE For Life beneficiaries (TRICARE FAQ, updated August 6, 2026). VA health care's criteria for Zepbound® are a BMI of 27 or more, a weight-related condition and a lifestyle program (VA criteria for use, April 2026); Indiana's VA medical centers are in Indianapolis, Marion and Fort Wayne (VA Indiana; VA Northern Indiana). Pokagon Band Health Services in Dowagiac, Michigan, serves Native Americans in northern Indiana (Pokagon Band).